Tempus AI (NASDAQ:TEM) Shares Down 4.1% After Insider Selling

Tempus AI, Inc. (NASDAQ:TEM) fell 4.1% during mid-day trading on Monday after an insider sold shares in the company. The company traded as low as $48.08 and last traded at $49.31. 8,476,573 shares were traded during trading, a decline of 8% from the average session volume of 9,223,558 shares. The stock had previously closed at $51.40.

Specifically, CEO Eric P. Lefkofsky sold 85,788 shares of the business’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $53.39, for a total value of $4,580,221.32. Following the sale, the chief executive officer now directly owns 5,771,787 shares of the company’s stock, valued at approximately $308,155,707.93. The trade was a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Eric P. Lefkofsky sold 476,209 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $49.84, for a total transaction of $23,734,256.56. Following the completion of the transaction, the chief executive officer now owns 6,502,643 shares of the company’s stock, valued at approximately $324,091,727.12. The trade was a 6.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analyst Ratings Changes

A number of analysts have recently commented on TEM shares. Wolfe Research started coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. Loop Capital decreased their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and upped their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Tempus AI in a research note on Tuesday, January 14th. Finally, Guggenheim started coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 price target for the company. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.36.

Tempus AI Stock Performance

The stock’s 50 day simple moving average is $44.26 and its 200 day simple moving average is $47.95. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI in the 3rd quarter worth approximately $30,000. FNY Investment Advisers LLC purchased a new position in Tempus AI during the fourth quarter valued at approximately $67,000. Vestor Capital LLC acquired a new position in shares of Tempus AI in the 3rd quarter valued at $153,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Tempus AI in the fourth quarter worth about $178,000. Finally, Stifel Financial Corp purchased a new position in Tempus AI during the third quarter worth approximately $218,000. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.